Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017

  • ID: 4311875
  • Report
  • 42 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Mithra Pharmaceuticals SA
  • PEPTONIC medical AB
  • TherapeuticsMD Inc
  • MORE
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline landscape.

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 2 respectively.

Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Mithra Pharmaceuticals SA
  • PEPTONIC medical AB
  • TherapeuticsMD Inc
  • MORE
  1. Introduction
  2. Vaginal Atrophy (Atrophic Vaginitis) - Overview
  3. Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development
  13. Allergan Plc
  14. Foamix Pharmaceuticals Ltd
  15. Mithra Pharmaceuticals SA
  16. PEPTONIC medical AB
  17. Sermonix Pharmaceuticals LLC
  18. TherapeuticsMD Inc
  19. Vaginal Atrophy (Atrophic Vaginitis) - Drug Profiles
  20. (estradiol + progesterone) - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. Estetrol - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. estradiol hemihydrate - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. lasofoxifene tartrate - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. oxytocin - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. WC-3011 - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects
  45. Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones
  46. Featured News & Press Releases
  47. Mar 01, 2017: Acerus Files a New Drug Submission for GYNOFLOR in Canada
  48. May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor
  49. Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study
  50. Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting
  51. Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting
  52. Jul 17, 2015: Last subject exits Peptonic Medical’s phase 2b VVA study
  53. Mar 23, 2015: Peptonic Medical’s formulation patent to be approved in the USA
  54. Mar 18, 2015: Patient recruitment to Peptonic Medical’s phase 2b study soon completed
  55. Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin
  56. Dec 01, 2014: Peptonic Medical’s formulation patent to be approved in Europe
  57. Oct 28, 2014: First patients included in Peptonic Medical AB’s clinical phase 2b study
  58. Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study
  59. Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study
  60. Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden
  61. Jan 05, 2012: Peptonic's Oxytocin Receives Approval For Dose-Finding Trial From Swedish Medical Products Agency
  62. Appendix
  63. Methodology
  64. Coverage
  65. Secondary Research
  66. Primary Research
  67. Expert Panel Validation
  68. Contact Us
  69. Disclaimer
List of Tables:
  1. Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1
  2. Number of Products under Development by Companies, H1
  3. Products under Development by Companies, H1
  4. Number of Products by Stage and Target, H1
  5. Number of Products by Stage and Mechanism of Action, H1
  6. Number of Products by Stage and Route of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
  8. Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Allergan Plc, H1
  9. Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd, H1
  10. Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals SA, H1
  11. Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by PEPTONIC medical AB, H1
  12. Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Sermonix Pharmaceuticals LLC, H1
  13. Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc, H1
  14. Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H1
List of Figures:
  1. Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Foamix Pharmaceuticals Ltd
  • Mithra Pharmaceuticals SA
  • PEPTONIC medical AB
  • Sermonix Pharmaceuticals LLC
  • TherapeuticsMD Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll